Obesity and Cancer
Oncology-Obesity
DOI:
https://doi.org/10.22376/ijtos.2023.1.4.38-51Keywords:
Cancer, inflammation, the microbiome, adipokines, adiponectin, biomarkers, obesity, resisting, visfatinAbstract
It is a key priority in public health to treat illnesses due to the rising frequency of obesity-related malignancies. Around 11.9% of male and 13.1% of female cancer cases worldwide have an obesity-related malignancy as their primary cause. In addition to colorectal, postmenopausal ovarian, breast, gallbladder, thyroid, and multiple myeloma cancers, endometrial, esophageal, hepatocellular carcinoma, gastric cancer, renal and pancreatic adenocarcinomas, and thyroid cancer, the relationship between obesity and cancer is clear in many anatomical sites. This article provides a thorough overview of the most recent epidemiological data on obesity and its connection to cancer in light of this urgent issue. The contradiction of weight increase and cancer risk and death. Furthermore, examining BMI differences in obesity-related malignancies offers a comprehensive grasp of the disease's complexities. These mechanisms include adipokine pathophysiology, cellular and micro environmental changes, ectopic fat accumulation, disruptions in dietary nutrients, circadian cycles, and potential factors like alteration of the intestinal flora and mechanical influences on weight. The conclusion's discussion of potential future approaches to prevention, detection, and treatment highlights the pressing need for more study and action on this important public health problem. The main objective is to increase knowledge of the complexity of obesity-related malignancies and increase awareness of it to create efficient methods for prevention and treatment. This review offers insight into how potential processes and risk factors combine on target tissues, ultimately causing them to take on a feature of cancer by addressing these important aspects. This review focuses on the Epidemiology of obesity influencing cancer, links between obesity and cancer, the influence of cancer by weight growth, somatometry, biological links, ectopic fat deposition, insulin sensitivity, adiponectin, obesity influencing widely occurring cancers, and FTO protein.
References
Probst LE. Options for refractive surgery in 1998. J Refract Surg 1998;14:491-3.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence andmortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer2015;136:E359-86.
Dalamaga M, Christodoulatos GS, Mantzoros CS. The role of extracellular and intracellularNicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives andchallenges. Metabolism 2018;82:72-87.
Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of currentevidence. Endocr Rev 2012;33:547-94.
Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N YAcad Sci 2012;1271:37-43.
Arnold M, Leitzmann M, Freisling H, Bray F, Romieu I, Renehan A, et al. Obesity and cancer: Anupdate of the global impact. Cancer Epidemiol 2016;41:8-15.
Berger NA. Obesity and cancer pathogenesis. Ann N Y Acad Sci 2014;1311:57-76.
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030.Int J Obes (Lond) 2008;32:1431-7.
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and nationalprevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-81
Pischon T, Nimptsch K. Obesity and Risk of Cancer: An Introductory Overview. Recent ResultsCancer Res 2016;208:1-15
Alford S, Patel D, Perakakis N, Mantzoros CS. Obesity as a risk factor for Alzheimer's disease:weighing the evidence. Obes Rev 2018;19:269-80.
Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a Disease. Med Clin North Am2018;102:13-33
Hefetz-Sela S, Scherer PE. Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacology & therapeutics. 2013 May 1;138(2):197-210.
Habanjar O, Diab-Assaf M, Caldefie-Chezet F, Delort L. The impact of obesity, adipose tissue, and tumor microenvironment on macrophage polarization and metastasis. Biology. 2022 Feb 21;11(2):339.
Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2013 Oct 1;1831(10):1533-41
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. Cancers. 2023 Jan 12;15(2):485
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer- Viewpoint of the IARC Working Group. N Engl J Med 2016;375:794-8.
Lane MM, Davis JA, Beattie S, Gómez‐Donoso C, Loughman A, O'Neil A, Jacka F, Berk M, Page R, Marx W, Rocks T. Ultraprocessed food and chronic noncommunicable diseases: a systematic review and meta‐analysis of 43 observational studies. Obesity Reviews. 2021 Mar;22(3):e13146.
Loomis D, Huang W, Chen G. The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: focus on China. Chinese journal of cancer. 2014 Apr;33(4):189.
Demicheli R, Fornili M, Ambrogi F, Higgins K, Boyd JA, Biganzoli E, Kelsey CR. Recurrence dynamics for non–small-cell lung cancer: effect of surgery on the development of metastases. Journal of Thoracic Oncology. 2012 Apr 1;7(4):723-30.
Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med 2014;62:96-102.
Doehner W, von Haehling S, Anker SD. Protective overweight in cardiovascular disease: moving from 'paradox' to 'paradigm'. Eur Heart J 2015;36:2729-32.
Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox in chronic disease: facts andnumbers. J Cachexia Sarcopenia Muscle 2012;3:1-4.
Marouga A, Dalamaga M, Kastania AN, Antonakos G, Thrasyvoulides A, Kontelia G, et al. Correlates of serum resistin in elderly, non-diabetic patients with chronic kidney disease. Clin Lab 2013;59:1121-8.
Ng PY, Eikermann M. The obesity conundrum in sepsis. 2017;17:147.
Tsang NM, Pai PC, Chuang CC, Chuang WC, Tseng CK, Chang KP, et al. Overweight and obesitypredict better overall survival rates in cancer patients with distant metastases. BMC Anesthesiol2016;5:665-75.
Bandera EV, Fay SH, Giovannucci E, Leitzmann MF, Marklew R, McTiernan A, et al. The use and interpretation of anthropometric measures in cancer epidemiology: A perspective from the worldcancer research fund international continuous update project. Int J Cancer 2016;139:2391-7.
Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst2015;107.
Birks S, Peeters A, Backholer K, O'Brien P, Brown W. A systematic review of the impact of weight loss on cancer incidence and mortality. Obes Rev 2012;13:868-91.
Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019 Mar 1;92:121-35.
Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, Kurshan N. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer research. 2010 Jan 15;70(2):741-51.
Papaioannou S, Tzafettas J. Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer. Best Practice & Research Clinical Obstetrics & Gynaecology. 2010 Feb 1;24(1):19-27.
Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019 Mar 1;92:121-35.
Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World journal of gastroenterology: WJG. 2014 May 5;20(18):5177.
Burhans MS, Hagman DK, Kuzma JN, Schmidt KA, Kratz M. Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Comprehensive Physiology. 2018 Dec 12;9(1):1.
Lazarus E, Bays HE. Cancer and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022. Obesity Pillars. 2022 Sep 1;3:100026.
Murphy WJ, Longo DL. The surprisingly positive association between obesity and cancer immunotherapy efficacy. Jama. 2019 Apr 2;321(13):1247-8.
Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 2015;15:484-98.
Dalamaga M, Christodoulatos GS. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Horm Mol Biol Clin Investig 2015;23:5-20.
Coe PO, O'Reilly DA, Renehan AG. Excess adiposity and gastrointestinal cancer. Br J Surg2014;101:1518-31; discussion 31.
Mauro L, Naimo GD, Ricchio E, Panno ML, Ando S. Cross-Talk between Adiponectin and IGF-IR in Breast Cancer. Front Oncol 2015;5:157.
Hanahan, D., Weinberg, R.A. 2011. Hallmarks of cancer: the next generation. Cell 144, 646-674
Prendergast, H.C., Metz, R., Muller, A.J. 2010. Towards a genetic definition of cancer associated inflammation: role of the IDO pathway. Amer J Pathol 176, 2082-2087.
Baena R, Salinas P. Diet and colorectal cancer. Maturitas. 2015 Mar 1;80(3):258-64.
Kim, S.H., Abbasi, F., Reaven, G.M. 2004. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 27, 1998-2002
Goodwin, P.J., Ennis, M., Pritchard, K.I., Trudeau, M,E,, Koo, J., Madarnas, Y., et al. 2002.Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20, 42-51.
Hsing, A.W., Chua, S., Gao, Y.T., Gentzschein, E., Chang, L., Deng, J. et al.2001. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Nat Cancer Inst 93, 783-789.
Lee, J., Lee, J., Farquhar, K.S., Yun, J., Frankenberger, C.A., Bevilacqua, E. et al. 2014.Network of mutually repressive metastasis regulators can promote cell heterogeneity andmetastatic transitions. Proc Nat Acad Sci USA 111, E364-E373.
Ma, J., Pollak, M.N., Giovannucci, E., Chan, J.M., Tao, Y., Hennekens, C.H., Stampfer, M.J. 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-likegrowth factor (IGF)-I and IGF-binding protein-3. J Nat Cancer Inst 91, 620-625.
Wolpin, B.M., Meyerhardt, J.A., Chan, A.T., Ng, K., Chan, J.A., Wu, K. et al. 2009. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectalcancer. J Clin Oncol 27, 176-185.
Augustin LS, Dal Maso L, La Vecchia C, Parpinel M, Negri E, Vaccarella S, Kendall CW, Jenkins DJ, Franceschi S. Dietary glycemic index and glycemic load, and breast cancer risk: a case-control study. Annals of Oncology. 2001 Nov 1;12(11):1533-8.
Bruce CR, Mertz VA, Heigenhauser GJ, Dyck DJ. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes. 2005 Nov 1;54(11):3154-60.
Kennedy L, Bittel DC, Kibiryeva N, Kalra SP, Torto R, Butler MG. Circulating adiponectin levels, body composition and obesity-related variables in Prader–Willi syndrome: comparison with obese subjects. International journal of obesity. 2006 Feb;30(2):382-7.
Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocrine reviews. 2012 Aug 1;33(4):547-94.
Harris BH, Macaulay VM, Harris DA, Klenerman P, Karpe F, Lord SR, Harris AL, Buffa FM. Obesity: A perfect storm for carcinogenesis. Cancer and Metastasis Reviews. 2022 Sep;41(3):491-515.
Wakil, S.J. 1989. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28,4523-4530.
Gansler, T.S., Hardman, W., Hunt, D.A., Schaffel, S., Hennigar, R.A. 1997. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Human Pathology 28, 686-692.
Keshk, W.A., Zineldeen, D.H., El-Khadrawy, O.H. 2014. Fatty acid synthase/oxidized lowdensity lipoprotein as metabolic oncogenes linking obesity to colon cancer via NF-kappa B in Egyptians. Med Oncol 31, 1-10.
Rossi, S., Ou, W., Tang, D., Bhattacharya, N., Dei, T.A.P., Fletcher, J.A. et al. 2006.Gastrointestinal stromal tumors overexpress fatty acid synthase. J Pathol 209, 369-375.
Kridel, S.J., Axelrod, F., Rozenkrantz, N., Smith, J.W. 2004. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Research 64, 2070-2075.
Seguin, F., Carvalho, M.A., Bastos, D.C., Agostini, M., Zecchin, K.G., Alvarez-Flores, M.P.et al. 2012. The fatty acid synthase inhibitor orlistat reduces experimental metastases andangiogenesis in B16-F10 melanomas. Brit J Cancer 107, 977-987.
Nguyen, P.L., Ma, J., Chavarro, J.E., Freedman, M.L., Lis, R., Fedele, G., Fiore, C. et al. 2010. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostatecancer risk, and survival. J Clin Oncol 28, 3958-3964.
Calle, E.E., Kaaks, R. 2004. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nature Revs Cancer 4, 579-591.
Musso, G., Gambino, R., Cassader, M. 2010. Obesity, Diabetes, and Gut Microbiota Thehygiene hypothesis expanded? Diabetes Care 33, 2277 -2284.
Cottam, D., Fisher, B., Ziemba, A., Atkinson, J., Grace, B., Ward, D.C. 2010. Tumor growth factor expression in obesity and changes in expression with weight loss: another cause ofincreased virulence and incidence of cancer in obesity. Surg Obesity Rel Dis 6, 538-541.
George, M.D., Giles, J.T., Katz, P.P., England, B.R., Mikuls, T.R., Michaud, K., et al. 2017.Impact of obesity and adiposity on inflammatory markers in patients with rheumatoidarthritis. Arthritis Care Res 69, 1789-1798.
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.Y., Vallabhapurapu, S. et al. 2009.IL-6 and Stat3 are required for survival of intestinal epithelial cells and development ofcolitis-associated cancer. Cancer Cell 15, 103-113.
Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. 2015;107(2).
Lopez-Suarez A. Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors. Metabolism. 2019;92:136-146.
Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36-46.
Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015;1(5):611-621.
Emaus MJ, van Gils CH, Bakker MF, et al. Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer. 2014;135(12):2887-2899.
Azrad M, Blair CK, Rock CL, Sedjo RL, Wolin KY, Demark-Wahnefried W. Adult weight gain accelerates the onset of breast cancer. Breast Cancer Res Treat. 2019
Berger NA. Young Adult Cancer: Influence of the Obesity Pandemic. Obesity (Silver Spring). 2018;26(4):641-650.
SEER Cancer Statistics Review, 1975-2014 Web site. https://seer.cancer.gov/csr/1975_2014/. Published 2016. Updated Updated June 28, 2017. Accessed May 28, 2019.
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer–viewpoint of the IARC Working Group. N Engl J Med2016;375:794 – 8.
Trentham-Dietz A, Newcomb PA, Storer BE, Longnecker MP, Baron J, Greenberg ER, Willett WC. Body size and risk of breast cancer. American journal of epidemiology. 1997 Jun 1;145(11):1011-9.
Nourazarian AR, Kangari P, Salmaninejad A. Roles of oxidative stress in the development and progression of breast cancer. Asian Pacific Journal of Cancer Prevention. 2014;15(12):4745-51.
Kesaniemi YA, Danforth E, Jensen MD, Kopelman PG, Lefèbvre PI, Reeder BA. Dose-response issues concerning physical activity and health: an evidence-based symposium. Medicine & Science in Sports & Exercise. 2001 Jun 1;33(6):S351-8.
Ali AT. Reproductive factors and the risk of endometrial cancer. International journal of gynecologic cancer. 2014 Mar 1;24(3).
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569 –78.
Steffen A, Huerta JM, Weiderpass E, Bueno-de-Mesquita HB, May AM, Siersema PD, et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2015;137:646 –57.
O’Doherty MG, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut 2012;61:1261– 8.
Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clinical endocrinology. 2006 Jul;65(1):125-31.
Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1996 Oct 15;78(8):1820-8.
Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon Jr LF, Metko V, Near E, Kellenberg J, Kalish T, Inadomi JM. Prediction of Barrett’s esophagus among men. The American journal of gastroenterology. 2013 Mar;108(3):353.
Hofseth LJ, Hebert JR, Chanda A, Chen H, Love BL, Pena MM, Murphy EA, Sajish M, Sheth A, Buckhaults PJ, Berger FG. Early-onset colorectal cancer: initial clues and current views. Nature reviews Gastroenterology & hepatology. 2020 Jun 15;17(6):352-64.
Nimptsch K, Steffen A, Pischon T. Obesity and oesophageal cancer. Obesity and Cancer. 2016:67-80.
Chevallier, J.M.; Chiappetta, S.; Musella, M. Obesity: Barrett’s Esophagus and Esophageal Cancer Risk. In Revisiting Barrett’s Esophagus; Springer: Berlin/Heidelberg, Germany, 2019; pp. 39–50.
Aune D, Mahamat-Saleh Y, Norat T, Riboli E. Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies. European journal of epidemiology. 2018 Nov;33:1033-47.
Gyamfi J, Kim J, Choi J. Cancer as a metabolic disorder. International journal of molecular sciences. 2022 Jan 21;23(3):1155.
Eskelinen TJ, Kotsar A, Tammela TL, Murtola TJ. Components of metabolic syndrome and prognosis of renal cell cancer. Scandinavian Journal of Urology. 2017 Nov 2;51(6):435-41.
Cozzo AJ, Fuller AM, Makowski L. Contribution of adipose tissue to development of cancer. Comprehensive Physiology. 2017 Dec 12;8(1):237.
Collaborative Group on Epidemiological Studies of Ovarian C. Ovarian cancer and body size: individual participant meta-analysis including 25 157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9:e1001200.
Ong JS, Cuellar-Partida G, Lu Y, Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International journal of epidemiology. 2016 Oct 1;45(5):1619-30.
Ke C, Hou Y, Zhang H, Fan L, Ge T, Guo B, Zhang F, Yang K, Wang J, Lou G, Li K. Large‐scale profiling of metabolic dysregulation in ovarian cancer. International journal of cancer. 2015 Feb 1;136(3):516-26.
Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, Pileri A, Giunti M, Falini B, Bolis GB, Stein H. Hodgkin's lymphoma: the pathologist's viewpoint. Journal of clinical pathology. 2002 Mar 1;55(3):162-76.
Pi-Sunyer X. The medical risks of obesity. Postgraduate medicine. 2009 Nov 1;121(6):21-33.
Galbraith D, Gross SA, Paustenbach D. Benzene and human health: a historical review and appraisal of associations with various diseases. Critical reviews in toxicology. 2010 Nov 1;40(sup2):1-46.
Azizian M, Mahdipour E, Mirhafez SR, Shoeibi S, Nematy M, Esmaily H, Ferns GA, Ghayour-Mobarhan M. Cytokine profiles in overweight and obese subjects and normal weight individuals matched for age and gender. Annals of Clinical Biochemistry. 2016 Nov;53(6):663-8.
Fardi M, Solali S, Hagh MF. Epigenetic mechanisms as a new approach in cancer treatment: An updated review. Genes & diseases. 2018 Dec 1;5(4):304-11.
Hosgood, H.D.; Gunter, M.J.; Murphy, N.; Rohan, T.E.; Strickler, H.D. The Relation of Obesity-Related Hormonal and Cytokine Levels With Multiple Myeloma and Non-Hodgkin Lymphoma. Front. Oncol. 2018, 8, 103.
World Cancer Research Fund International/AmericanInstitute for Cancer Research. Continuous Update Project Report: Diet, nutrition, physical activity and gallbladdercancer. 2015.
Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney international. 2008 Jan 1;73(1):19-33.
Friedenreich CM, Ryder‐Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Molecular oncology. 2021 Mar;15(3):790-800.
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer–viewpoint of the IARC Working Group. N Engl J Med2016;375:794 – 8.
Milic´ S, Lulic´ D, Sˇ timac D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 2014;20:9330 –7.
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S,Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428 –33;quiz e50.
Ohishi W, Cologne JB, Fujiwara S, Suzuki G, Hayashi T, Niwa Y, Akahoshi M, Ueda K, Tsuge M, Chayama K. Serum interleukin‐6 associated with hepatocellular carcinoma risk: A nested case–control study. International journal of cancer. 2014 Jan 1;134(1):154-63.
Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nature Clinical Practice Endocrinology & Metabolism. 2007 Jun;3(6):458-69.
Azzam SK, Alsafar H, Sajini AA. FTO m6A demethylase in obesity and cancer: implications and underlying molecular mechanisms. International journal of molecular sciences. 2022 Mar 30;23(7):3800.
Kang Y, Liu F, Liu Y. Is FTO gene variant related to cancer risk independently of adiposity? An updated meta-analysis of 129,467 cases and 290,633controls. Oncotarget (2017) 8:50987–96. doi: 10.18632/oncotarget.16446
Umapathy VR, Natarajan PM, Swamikannu B, Moses J, Jones S, Chandran MP et al. Emerging Biosensors for Oral Cancer Detection and Diagnosis-A Review Unravelling Their Role in Past and Present Advancements in the Field of Early Diagnosis. Biosensors. 2022;12(7):498. doi: 10.3390/bios12070498, PMID 35884301.
Rekha U V, Mn P, S B. Review on Anticancer properties of piperine in Oral cancer: therapeutic Perspectives. Res J Pharm Technol. 2022;15(7):3338-42. doi: 10.52711/0974-360X.2022.00558.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr Somenath Ghosh, Kiruthika Balasubramanian, J Andrews Milton, Dr Vinayak B Angadi, Hadi Kuriri, Dr Umesh Ghate, Dr Radhika Ketkar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
